# VEBrant (NCT07153887)

> Vebreltinib for Advanced or Metastatic CCS

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07153887
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions: Clear Cell Sarcoma (CCS)
- Interventions: Vebreltinib; Standard medical treatment
- Enrollment: 30
- Primary outcome: ORR

## Indexed commentary on VEBrant so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=vebrant-nct07153887